Achieving clinical remission in moderate-to-severe asthma using inhaled triple therapy

ERJ Open Research 2026 Open access

Read full text
Authors: Giorgio Walter Canonica, Dave Singh, Alberto A. Papi, Guy Brusselle, Alessio Piraino, Laura Franzini, Andrea Vele, Gemzel A. Hernandez, Gwen Skloot, J Christian Virchow
DOI: 10.1183/23120541.00054-2026
Cited by: 1
References: 33

Abstract

Background There is growing interest in evaluating the ability of treatments to deliver clinical remission in patients with asthma. We conducted post hoc analyses of TRIMARAN and TRIGGER, two clinical studies comparing the efficacy and safety of fixed-dose combination beclometasone dipropionate (BDP), formoterol fumarate (FF) and glycopyrronium (G) (TRIMARAN, 100/6/10 μg and TRIGGER 200/6/10 µg) with BDP/FF (100/6 µg and 200/6 µg, respectively). Methods Clinical remission was defined as: no use of oral corticosteroids over 52 weeks, no occurrence of severe exacerbations over 52 weeks, Asthma Control Questionnaire-5 score

Fields of Study & Subjects

Asthma and respiratory diseases Inhalation and Respiratory Drug Delivery Allergic Rhinitis and Sensitization

Publication details

Journal / source
ERJ Open Research
Publisher
European Respiratory Society (ERS)
Volume
12
Issue
5
Pages
00054–2026
Publication date
23 April 2026
Language
EN